Table 3 Comparisons of clinical characteristics of pMN patients with different severity of chronic tubulointerstitial injury
From: Clinical implications of pathological features of primary membranous nephropathy
|  | Grade = 0 (n = 100) | Grade = 1 (n = 56) | Grade = 2 (n = 207) | Grade = 3 (n = 8) | P |
|---|---|---|---|---|---|
Age (year) | 47 (32–58) | 54 (44–62) | 56 (47–63) | 58 (50–70) | < 0.001 |
Gender (M/F) | 49/51 | 34/22 | 121/86 | 3/5 | 0.252 |
Nephrotic syndrome, n (%) | 51 (51.0%) | 37 (66.1%) | 161 (77.8%) | 6 (75.0%) | < 0.001 |
Proteinuria (g/24 h) | 2.8 (1.8–4.8) | 3.8 (2.0–6.3) | 4.8 (2.9–7.3) | 7.6 (4.0–11.1) | < 0.001 |
Serum albumin (g/L) | 29.6 ± 5.7 | 29.3 ± 7.0 | 26.0 ± 5.7 | 26.3 ± 4.8 | < 0.001 |
Microscopic hematuria, n (%) | 50 (50.0%) | 36 (64.3%) | 118 (57.6%) | 4 (50.0%) | 0.422 |
Serum creatinine (μmol/L) | 61.3 (50.9–72.9) | 66.2 (52.8–78.9) | 67.3 (55.0–83.0) | 133.4 (99.5–174.6) | < 0.001 |
eGFR (ml/min per 1.73m2) | 123.1 (105.4–151.5) | 115.5 (96.9–146.9) | 109.8 (85.8–139.5) | 49.1 (29.3–70.5) | < 0.001 |
Anti-PLA2R antibody positivity, n (%) | 54 (54.0%) | 36 (64.3%) | 147 (71.4%) | 6 (85.7%) | 0.016 |
Anti-PLA2R antibody level (U/mL) | 105.9 (46.5–195.2) | 106.4 (61.6–181.8) | 117.8 (51.8–241.1) | 299.3 (40.6–818.90) | 0.659 |
Anti-THSD7A antibody positivity, n (%) | 2 (2.6%) | 0(0.0%) | 2 (1.2%) | 0 (0.0%) | 0.657 |
Hypertension, n (%) | 33 (33.0%) | 24 (42.9%) | 123 (59.4%) | 7 (87.5%) | < 0.001 |
Hemoglobin (g/L) | 139.0 (128.0–152.0) | 137.0 (130.0–150.0) | 136.0 (123.0–147.0) | 107.0 (120.8–131.5) | 0.004 |